Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, enGene Holdings's Enterprise Value is $506.02 Mil.
enGene Holdings's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was $-98.88 Mil. Therefore, enGene Holdings's EV-to-EBIT ratio for today is -5.12.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, enGene Holdings's Enterprise Value is $506.02 Mil.
enGene Holdings's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was $-98.67 Mil. Therefore, enGene Holdings's EV-to-EBITDA ratio for today is -5.13.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, enGene Holdings's Enterprise Value is $506.02 Mil.
enGene Holdings's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 was $0.00 Mil. Therefore, enGene Holdings's EV-to-Revenue ratio for today is .
enGene Holdings Enterprise Value Historical Data
The historical data trend for enGene Holdings's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of enGene Holdings's Enterprise Value
For the Biotechnology subindustry, enGene Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Holdings's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Holdings's Enterprise Value distribution charts can be found below:
* The bar in red indicates where enGene Holdings's Enterprise Value falls into.
enGene Holdings Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
enGene Holdings's Enterprise Value for the fiscal year that ended in Oct. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Holdings (NAS:ENGN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
enGene Holdings's current Enterprise Value is $506.02 Mil.
enGene Holdings's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-98.88 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
enGene Holdings's current Enterprise Value is $506.02 Mil.
enGene Holdings's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-98.67 Mil.
enGene Holdings's current Enterprise Value is $506.02 Mil.
enGene Holdings's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Holdings Enterprise Value Related Terms
Thank you for viewing the detailed overview of enGene Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
enGene Holdings (enGene Holdings) Business Description
7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9
Website
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENGN has been successfully added to your 